Author:

Keywords:

Science & Technology, Life Sciences & Biomedicine, Neurosciences, Neurosciences & Neurology, microRNA, Alzheimer's disease, therapeutics, neurodegenerative diseases, AMYLOID PRECURSOR PROTEIN, CHRONIC HEPATITIS-C, NF-KAPPA-B, ADENOASSOCIATED VIRUS, CELLULAR-PHASE, NONCODING RNA, ANIMAL-MODEL, DOUBLE-BLIND, MOUSE MODEL, OPEN-LABEL, Alzheimer’s disease, Alzheimer Disease, Brain, Humans, MicroRNAs, 0604 Genetics, 1103 Clinical Sciences, 1109 Neurosciences, Neurology & Neurosurgery, 3101 Biochemistry and cell biology, 3209 Neurosciences

Abstract:

Multi-pathway approaches for the treatment of complex polygenic disorders are emerging as alternatives to classical monotarget therapies and microRNAs are of particular interest in that regard. MicroRNA research has come a long way from their initial discovery to the cumulative appreciation of their regulatory potential in healthy and diseased brain. However, systematic interrogation of putative therapeutic or toxic effects of microRNAs in (models of) Alzheimer's disease is currently missing and fundamental research findings are yet to be translated into clinical applications. Here, we review the literature to summarize the knowledge on microRNA regulation in Alzheimer's pathophysiology and to critically discuss whether and to what extent these increasing insights can be exploited for the development of microRNA-based therapeutics in the clinic.